Drug – bio-affecting and body treating compositions – Extract or material containing or obtained from a...
Reexamination Certificate
2001-02-25
2004-07-06
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Extract or material containing or obtained from a...
C424S439000, C514S055000, C514S826000, C514S836000, C514S866000, C514S879000, C514S909000
Reexamination Certificate
active
06759049
ABSTRACT:
The present invention relates to the field of pharmacy and dietetics.
A more particular subject of the present invention is new pharmaceutical and/or dietary compositions with a fungi base.
A specific subject of the invention is pharmaceutical and/or dietary compositions combining one or more edible fungi having therapeutic properties, and chitosan.
With the increase, in particular in Western societies, of certain diseases linked to problems of environment or to poor diet, such as cancer, diabetes or cardiovascular diseases, some in the medical profession agree with the nutritionists on this, and increasingly stress the importance of a healthy diet to prevent, and even combat these diseases.
Among the various foodstuffs proposed, edible fungi present interesting therapeutic properties. Thus they are said to possess, as the case may be, immunostimulant, slimming, hypoglycaemic, anti-hypertensive, even anticancerous and antiviral properties. Scientific work increasingly corroborates their medical significance.
Fungi contain on average:
0.5 to 1.5% mineral substances such as potassium, calcium, magnesium, phosphorus, zinc, copper, sulphur, sodium and above all selenium;
approximately 4% assimillable proteins, in particular lysine;
approximately 3.5% glucides such as polysaccharides, lectins containing large quantities of galactose, xylose, arabinose, fucose, rhamnose and mannose;
0.05 to 2% lipids;
vitamins and in particular group B vitamins, namely vitamin B1, vitamin B2, pantothenic acid (vitamin B5), folic acid (vitamin B9), nicotinic acid (vitamin B3); vitamin C; vitamin D2; vitamin E; vitamin PP and vitamin K.
The active ingredients of fungi are complex branched polysaccharides or strongly glycosylated, neutral or weakly basic proteins.
However, fungi present the major drawback of accumulating toxic substances of all kinds. In fact, they concentrate minerals and in particular heavy metals, in particular lead, cadmium, manganese, arsenic, mercury.
Consumption of these heavy metals is not without an effect on health. Thus:
lead poisoning is in particular the cause of saturnism either in its acute form which manifests itself in violent intestinal pains or in its chronic form which manifests itself by nervous disorders, interstitial nephritis, haematological disorders, saturnine cachexia which can lead to death;
excess of manganese can cause Parkinson's disease as reported by Huang CC et al. (Neurology 1998;50:698-700);
the toxicity of cadmium is substantial and can induce vomiting, abdominal pains, severe diarrhoea and a fall in blood pressure. Following prolonged contact, it can attach itself to the thiol groups of proteins, in the erythrocytes, in the kidney, causing proximal tubulopathy, but also in the bone and the liver. It is thus reportedly the source of cancers such as that of the liver and the prostata;
arsenic which is contained in insecticides and fungicides, can cause vomiting, abdominal pains, cyanosis, respiratory problems. . .
mercury, for example methyl mercury, triggers bloody vomiting, abdominal spasms, bloody diarrhoea and renal insufficiency. A patient subjected to chronic exposure to mercury can present digestive, renal, cutaneous or nervous disorders. Acute mercury poisoning can manifest itself in tubulo-interstitial nephropathy, encephalopathy or anuria.
Fungi also accumulate weed killer, fertilizers and insecticides.
Finally, fungi also present lesser or greater radioactivity levels according to their nature, their enzymatic capacity, the physical location of their habitat (meadow, clearing, non-coniferous or coniferous forests) on the ground or on stumps or also according to the implantation depth of the mycelium. In fact, this radioactivity essentially results from the ability which fungi have, unlike chlorophyllous plants, to also concentrate radioactive metals, such as caesium 134, caesium 137, lead 210 and radium 226.
The consumption of such radioactive metals—for example caesium 137 the half-life of which is nearly 30 years—beyond European standards, would increase the risk of cancer, the number of congenital deformities or of genetic anomalies transmissible from generation to generation (CRII-RAD (Commission de Recherche et d'Information Indepéndantes sur la Radioactivité) Information sheet n°3 November 1997).
Therefore, if a completely safe pharmaceutical or even food use of these is desired, it is currently necessary to carry out the extraction of the active ingredients of the fungi in order to prevent possible contamination or to be ensured of the absence of the latter by carrying out analyses such as for example post-desiccation gamma spectrometry.
Both the extraction and the analysis operations are long, fastidious and consequently expensive.
The problem addressed by the present invention is to create fungi-based compositions which do not have to undergo prior treatments to remove possible contamination caused by heavy metals, radioactive metals from weed-killers, fertilizers and insecticides, or which have not been specially chosen beforehand to ensure the absence of contaminants.
The invention therefore consists of the combining, in pharmaceutical or dietary compositions, of one or more fungi or parts of edible fungi, presenting therapeutic (vitamins, compounds displaying dietary or therapeutic properties), and chitosan without having to carry out a prior treatment of the fungi of the purification type such as for example column extraction or purification.
The applicant has in fact found that chitosan allows a progressive release of the active ingredients contained in the fungus and ensures chelation of the contaminants.
Moreover, the release of the active ingredients from the fungus is progressive and thus manifests itself in an action and an efficacy which lasts over time compared with the effect obtained by taking an isolated extract from the same fungus.
Chitosan has a chemical structure close to that of cellulose and similar to plant fibers, it is not digested by the human body. It is a natural component and it allows the fiber content of the fungi to increase. Chitosan attaches itself onto the pre-existing skeleton of the fungus and onto the polysaccharides according to the pH. It will be released in the intestinal tract, also according to the prevailing pH there.
The extent of the increase in the level of chitosan in cultivated fungi, with chitosan, can be moderate or substantial, and optionally exceed the natural chitin and chitosan content of wild fungi, which are often more ligneous and therefore richer in structural support elements.
Chitosan is a linear polysaccharide constituted by a long chain of glucosamines linked by &bgr;(1-4)glucosidic bridges. It has the following chemical structure:
It results from the deacetylation of chitin. Chitin is the second most important polysaccharide present in nature after cellulose and is also found in the exoskeleton of crustaceans, of myriapods and of arthropods as well as in insects and fungi. The rate of deacetylation can vary from 80 to 100% according to the variety of chitosan and its average molecular weight is between 5 000 and 1 000000 making it possible to ensure the solubility, the turbidity and the viscosity of the compositions according to the invention.
Besides the fact of being non-toxic and non-allergising, it has in addition the advantage of being antibacterial, antifungal and antiviral. The use of chitosan in the pharmaceutical field has already been reported in numerous publications.
Thus, it was observed that chitosan would make it possible at one and the same time to reduce LDL cholesterol which, in excess, can settle in the tissues, in particular on the walls of the arteries and increase HDL cholesterol which is considered to be <<good>> cholesterol (Maezaki Y, Tsuji K, Nakagawa Y, et al. Bioscience Biotechnology Biochem 1993; 57(9):1439-44).
Other authors have confirmed that chitosan appears to be an effective hypocholesterolemic, agent by studying its action in rats (Sugano et al Nutritional Rep. Int., 1978;18(5):531-7).
A Chinese publication re
Flood Michele C.
Medecine Information Formation S.A.
Muserlian Lucas and Mercanti
Tate Christopher R.
LandOfFree
Pharmaceutical or dietetic mushroom-based compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical or dietetic mushroom-based compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical or dietetic mushroom-based compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3256859